Few developments have generated as much excitement — and debate — as the emergence of GLP-1 receptor agonists for weight loss. These medications, originally developed for diabetes, have shown remarkable efficacy in helping patients shed pounds.

But now, a new contender has entered the ring, and the results are hard to ignore. A recent study published in the New England Journal of Medicine offers the first head-to-head comparison between two of the most talked-about drugs in obesity management: semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound).

The findings are striking because tirzepatide beat out semaglutide and led to greater weight loss and a greater reduction in waist circumference.

And this was no small trial. The SURMOUNT-5 study enrolled 751 participants and randomized them to receive either tirzepatide or semaglutide at their maximum tolerated doses. At the end of the 72 week study, those on tirzepatide had lost an average of 20 per cent of their body weight, compared to 14 per cent for........

© Montreal Gazette